141 related articles for article (PubMed ID: 30191532)
1. Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study.
Guadagni S; Clementi M; Bencivenga M; Kusamura S; Fiorentini C; Masedu F
Updates Surg; 2018 Dec; 70(4):441-447. PubMed ID: 30191532
[TBL] [Abstract][Full Text] [Related]
2. Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study.
Guadagni S; Fiorentini G; Palumbo P; Masedu F; Ricevuto E; Bruera G; Deraco M; Kusamura S; Sarti D; Fiorentini C; Gailhofer S; Clementi M
Minerva Chir; 2019 Aug; 74(4):304-312. PubMed ID: 31062943
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer.
Guadagni S; Fiorentini G; Palumbo G; Valenti M; Russo F; Cantore M; Deraco M; Vaglini M; Amicucci G
Arch Surg; 2001 Jan; 136(1):105-12. PubMed ID: 11146790
[TBL] [Abstract][Full Text] [Related]
4. Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques.
Guadagni S; Fiorentini G; Clementi M; Palumbo P; Mambrini A; Masedu F
Updates Surg; 2017 Sep; 69(3):403-410. PubMed ID: 28791628
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study.
Guadagni S; Fiorentini G; Mambrini A; Masedu F; Valenti M; Mackay AR; Sarti D; Ricevuto E; Clementi M; Catarci M; Lazzarin G; Bruera G
Oncotarget; 2019 Jun; 10(39):1-13. PubMed ID: 31231460
[TBL] [Abstract][Full Text] [Related]
6. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial.
van Ijken MG; van Etten B; Guetens G; de Bruijn EA; Ten Hagen TL; Wiggers T; Eggermont AM
Eur J Surg Oncol; 2005 Oct; 31(8):897-904. PubMed ID: 16084053
[TBL] [Abstract][Full Text] [Related]
7. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
8. Pelvic perfusion for locally recurrent unresectable rectal tumors.
Unal AE; Bayar S; Tez M; Gocmen E; Kocaoglu H; Akgul H
Hepatogastroenterology; 2005; 52(63):757-60. PubMed ID: 15966199
[TBL] [Abstract][Full Text] [Related]
9. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
Wanebo HJ; DiSiena M; Begossi G; Belliveau J; Gustafson E
Ann Surg Oncol; 2008 Apr; 15(4):1107-16. PubMed ID: 18157578
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer.
Guadagni S; Aigner KR; Palumbo G; Cantore M; Fiorentini G; Pozone T; Deraco M; Clerico M; Chaudhuri PK
J Clin Pharmacol; 1998 Oct; 38(10):936-44. PubMed ID: 9807975
[TBL] [Abstract][Full Text] [Related]
11. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.
Guadagni S; Fiorentini G; De Simone M; Masedu F; Zoras O; Mackay AR; Sarti D; Papasotiriou I; Apostolou P; Catarci M; Clementi M; Ricevuto E; Bruera G
J Cancer Res Clin Oncol; 2020 Jan; 146(1):205-219. PubMed ID: 31620896
[TBL] [Abstract][Full Text] [Related]
12. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Turk PS; Belliveau JF; Darnowski JW; Weinberg MC; Leenen L; Wanebo HJ
Arch Surg; 1993 May; 128(5):533-8; discussion 538-9. PubMed ID: 7683872
[TBL] [Abstract][Full Text] [Related]
13. Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers.
Strocchi E; Iaffaioli RV; Facchini G; Mantovani G; Ricci S; Cavallo G; Tortoriello A; D'Angelo R; Formato R; Rosato G; Fiore F; Iaccarino V; Petrella G; Memoli B; Santangelo M; Camaggi CM
Eur J Surg Oncol; 2004 Aug; 30(6):663-70. PubMed ID: 15256242
[TBL] [Abstract][Full Text] [Related]
14. Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.
Guadagni S; Russo F; Rossi CR; Pilati PL; Miotto D; Fiorentini G; Deraco M; Santinami M; Palumbo G; Valenti M; Amicucci G
Am J Surg; 2002 Jan; 183(1):28-36. PubMed ID: 11869699
[TBL] [Abstract][Full Text] [Related]
15. Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer.
Vaglini M; Cascinelli F; Chiti A; Deraco M; Inglese MG; Rebuffoni G; Rizzi M; Sala B; Santoro N; Santinami M
Tumori; 1996; 82(5):459-62. PubMed ID: 9063524
[TBL] [Abstract][Full Text] [Related]
16. Curative potential of multimodality therapy for locally recurrent rectal cancer.
Hahnloser D; Nelson H; Gunderson LL; Hassan I; Haddock MG; O'Connell MJ; Cha S; Sargent DJ; Horgan A
Ann Surg; 2003 Apr; 237(4):502-8. PubMed ID: 12677146
[TBL] [Abstract][Full Text] [Related]
17. Intraarterial 5-FU-infusion and simultaneous radiotherapy as palliative treatment of recurrent rectal cancer.
Schnabel T; Zamboglou N; Kuhn FP; Kolotas C; Schmitt G
Strahlenther Onkol; 1992 Oct; 168(10):584-7. PubMed ID: 1279822
[TBL] [Abstract][Full Text] [Related]
18. Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer.
Lorenz M; Petrowsky H; Heinrich S; Janshon G; Staib-Sebler E; Poloczek Y; Gog C; Oremek G; Encke A
Eur J Surg Oncol; 1998 Dec; 24(6):542-7. PubMed ID: 9870731
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
20. Unresectable and locally recurrent rectal cancer treated with radiotherapy or bilateral internal iliac artery infusion of 5-fluorouracil.
Carlsson G; Hafström L; Jönsson PE; Ask A; Kallum B; Lunderquist A
Cancer; 1986 Jul; 58(2):336-40. PubMed ID: 2424584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
